MedPath

Sodium Sulfacetamide 9.8% Sulfur 4.8% Cleanser

Sodium Sulfacetamide 9.8% Sulfur 4.8% Cleanser

Approved
Approval ID

400646ae-94d1-4825-a737-161c4128e9d8

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Aug 26, 2025

Manufacturers
FDA

Oncor Pharmaceuticals

DUNS: 119032580

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Sodium Sulfacetamide 9.8% Sulfur 4.8%

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code83720-546
Product Classification
G
Generic Name
Sodium Sulfacetamide 9.8% Sulfur 4.8%
Product Specifications
Route of AdministrationTOPICAL
Effective DateAugust 26, 2025
FDA Product Classification

INGREDIENTS (18)

ALOE VERA LEAFInactive
Code: ZY81Z83H0X
Classification: IACT
BUTYLATED HYDROXYTOLUENEInactive
Code: 1P9D0Z171K
Classification: IACT
CETYL ALCOHOLInactive
Code: 936JST6JCN
Classification: IACT
CITRIC ACIDInactive
Code: 2968PHW8QP
Classification: IACT
COCAMIDOPROPYL BETAINEInactive
Code: 5OCF3O11KX
Classification: IACT
EDETATE DISODIUMInactive
Code: 7FLD91C86K
Classification: IACT
GLYCERINInactive
Code: PDC6A3C0OX
Classification: IACT
GLYCERYL STEARATE SEInactive
Code: FCZ5MH785I
Classification: IACT
PEG-100 STEARATEInactive
Code: YD01N1999R
Classification: IACT
PHENOXYETHANOLInactive
Code: HIE492ZZ3T
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
SODIUM LAURETH SULFATEInactive
Code: BPV390UAP0
Classification: IACT
SODIUM THIOSULFATEInactive
Code: HX1032V43M
Classification: IACT
STEARYL ALCOHOLInactive
Code: 2KR89I4H1Y
Classification: IACT
TRIACETINInactive
Code: XHX3C3X673
Classification: IACT
XANTHAN GUMInactive
Code: TTV12P4NEE
Classification: IACT
SULFACETAMIDE SODIUMActive
Quantity: 98 mg in 1 g
Code: 4NRT660KJQ
Classification: ACTIB
SULFURActive
Quantity: 48 mg in 1 g
Code: 70FD1KFU70
Classification: ACTIB

Drug Labeling Information

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

LOINC: 51945-4Updated: 8/14/2025

Manufactured In USA For :
Oncor Pharmaceuticals
6755 Business Pkwy Suite 202
Elkridge, MD 21075
United States.
Rev. 08/25

SS 9.8 - 4.8 Cleanser

INDICATIONS & USAGE SECTION

LOINC: 34067-9Updated: 8/14/2025

INDICATIONS

Sodium Sulfacetamide 9.8% & Sulfur 4.8% Cleanser is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.

CONTRAINDICATIONS SECTION

LOINC: 34070-3Updated: 8/14/2025

CONTRAINDICATIONS

Sodium Sulfacetamide 9.8% & Sulfur 4.8% Cleanser is contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur or any other component of this preparation. Sodium Sulfacetamide 9.8% & Sulfur 4.8% Cleanser is not to be used by patients with kidney disease.

ADVERSE REACTIONS SECTION

LOINC: 34084-4Updated: 8/14/2025

ADVERSE REACTIONS

Although rare, sodium sulfacetamide may cause local irritation. Call your doctor for medical advice about side effects.

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

LOINC: 34083-6Updated: 8/14/2025

CARCINOGENESIS, MUTAGENESIS AND IMPAIRMENT OF FERTILITY

Long-term studies in animals have not been performed to evaluate carcinogenic potential.

INSTRUCTIONS FOR USE SECTION

LOINC: 59845-8Updated: 8/14/2025

FOR EXTERNAL USE ONLY. NOT FOR INTRA VAGINAL OR OPHTHALMIC USE. (KEEP AWAY FROM EYES).
KEEP OUT OF REACH OF CHILDREN.
Shake well before use

DOSAGE & ADMINISTRATION SECTION

LOINC: 34068-7Updated: 8/14/2025

DOSAGE AND ADMINISTRATION

Wash affected area once or twice daily, or as directed by your physician. Avoid contact with eyes or mucous membranes. Wet skin and liberally apply to areas to be cleansed, massage gently into skin for 10-20 seconds working into a full lather, rinse thoroughly and pat dry. If drying occurs, it may be controlled by rinsing cleanser off sooner or using less often.

DESCRIPTION SECTION

LOINC: 34089-3Updated: 8/14/2025

DESCRIPTION

Sodium sulfacetamide is a sulfonamide with antibacterial activity while sulfur acts as a keratolytic agent.

Chemically sodium sulfacetamide is N-[(4-aminophenyl) sulfonyl)-acetamide, monosodium salt, monohydrate. The structural formula is: structure

Each gram of Sodium Sulfacetamide 9.8% and Sulfur 4.8% Cleanser contains 98 mg of sodium sulfacetamide and 48 mg of sulfur in a cleanser containing Aloe vera leaf extract, Butylated hydroxytoluene, Cetyl alcohol, Citric acid, Cocamidopropyl betaine, Disodium EDTA, Glycerin, Glyceryl stearate SE, PEG-100 stearate, Phenoxyethanol, Purified water, Sodium laureth sulfate, Sodium thiosulfate, Stearyl alcohol, Triacetin, Xanthan gum.

PRECAUTIONS SECTION

LOINC: 42232-9Updated: 8/14/2025

CAUTION

If redness or irritation occurs, discontinue use.

STORAGE AND HANDLING SECTION

LOINC: 44425-7Updated: 8/14/2025

STORAGE

Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (between 59°F and 86°F). Brief exposure to temperatures up to 40°C (104°F) may be tolerated provided the mean kinetic temperature does not exceed 25°C (77°F); however, such exposure should be minimized.

OTHER SAFETY INFORMATION

LOINC: 60561-8Updated: 8/14/2025

In case of accidental ingestion contact a Poison Control Center immediately. Keep container tightly closed.

You may report side effects by ca ling Oncor Pharmaceuticals (9 a.m. to 5 p.m. EST), at 1-443-876-7600 or FDA at 1-800-FDA-1088.

CLINICAL PHARMACOLOGY SECTION

LOINC: 34090-1Updated: 8/14/2025

CLINICAL PHARMACOLOGY

Sodium sulfacetamide exerts a bacteriostatic effect against sulfonamide sensitive gram-positive and gram-negative microorganisms commonly isolated from secondary cutaneous pyogenic infections. It acts by restricting the synthesis of folic acid required by bacteria for growth, by its competition with para-aminobenzoic acid. There is no clinical data available on the degree and rate of systemic absorption of this product when applied to the skin or scalp. However, significant absorption of sodium sulfacetamide through the skin has been reported.

The following in vitro data is available but the clinical significance is unknown. Organisms that show susceptibility to sodium sulfacetamide are: Streptococci, Staphylococci, E. coli, Klebsiella pneumoniae, Pseudomonas pyocyanea, Salmone la species, Proteus vulgaris, Nocardia and Actinomyces.

The exact mode of action of sulfur in the treatment of acne is unknown, but it has been reported that it inhibits the growth of Propionibacterium acnes and the formation of free fatty acids.

WARNINGS SECTION

LOINC: 34071-1Updated: 8/14/2025

WARNINGS

Although it is rare, sensitivity to sodium sulfacetamide may occur. Therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfonamides. Systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice, and contact dermatitis indicate hypersensitivity to sulfonamides. Particular caution should be employed if areas of denuded or abraded skin are involved.

GENERAL PRECAUTIONS SECTION

LOINC: 34072-9Updated: 8/14/2025

PRECAUTIONS

GENERAL

If irritation develops, use of the product should be discontinued and appropriate therapy instituted. Patients should be carefully observed for possible local irritation or sensitization during long-term therapy. The object of this therapy is to achieve desquamation without irritation, but sodium sulfacetamide and sulfur can cause reddening and scaling of the epidermis. These side effects are not unusual in the treatment of acne vulgaris, but patients should be cautioned about the possibility.

INFORMATION FOR PATIENTS SECTION

LOINC: 34076-0Updated: 8/14/2025

INFORMATION FOR PATIENTS

Avoid contact with eyes, eyelids, lips and mucous membranes. If accidental contact occurs, rinse with water. If excessive Irritation develops, discontinue use and consult your physician.

PREGNANCY SECTION

LOINC: 42228-7Updated: 8/14/2025

PREGNANCY

Category C

Animal reproduction studies have not been conducted with Sodium Sulfacetamide 9.8% & Sulfur 4.8% Cleanser. It is also not known whether Sodium Sulfacetamide 9.8% & Sulfur 4.8% Cleanser can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium Sulfacetamide 9.8% & Sulfur 4.8% Cleanser should be given to a pregnant woman only if clearly needed.

NURSING MOTHERS SECTION

LOINC: 34080-2Updated: 8/14/2025

NURSING MOTHERS

It is not known whether sodium sulfacetamide is excreted in the human milk following topical use of Sodium Sulfacetamide 9.8% & Sulfur 4.8% Cleanser. However, small amounts of orally administered sulfonamides have milk. In view of this and because many drugs are excreted in human milk, caution should be exercised when Sodium Sulfacetamide 9.8% & Sulfur 4.8% Cleanser is administered to a nursing woman.

PEDIATRIC USE SECTION

LOINC: 34081-0Updated: 8/14/2025

PEDIATRIC USE

Safety and effectiveness in children under the age of 12 have not been established.

HOW SUPPLIED SECTION

LOINC: 34069-5Updated: 8/14/2025

HOW SUPPLIED

Sodium Sulfacetamide 9.8% & Sulfur 4.8% Cleanser is available:
16 oz (454 g) bottle, NDC 83720-546-16.

SPL UNCLASSIFIED SECTION

LOINC: 42229-5Updated: 8/14/2025

NOTICE

Protect from freezing and excessive heat. The product may tend to darken slightly on storage. Slight discoloration does not impair the efficacy or safety of the product. Keep bottle tightly closed.

Occasionally, a slight discoloration of fabric may occur when an excessive amount of the product is used and comes in contact with white fabrics. This discoloration, however, presents no problem, as it is readily removed by ordinary laundering without bleaches.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Sodium Sulfacetamide 9.8% Sulfur 4.8% Cleanser - FDA Drug Approval Details